Using polyglycolic acid mesh to prevent cerebrospinal fluid leakage after pituitary tumor surgery
Using Polyglycolic Acid Mesh Prevents Cerebrospinal Fluid Leakage: Clinical Application to Endoscopic Endonasal Transsphenoidal Surgery
This study is testing if a special absorbable mesh can help prevent leaks of cerebrospinal fluid after surgery for pituitary tumors.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 20 Years and up |
| Sex | All |
| Sponsor | National Taiwan University Hospital Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Taipei) |
| Trial ID | NCT06472505 on ClinicalTrials.gov |
What this trial studies
This study investigates the effectiveness of polyglycolic acid (PGA) mesh, known as Neoveil, in preventing cerebrospinal fluid (CSF) leakage following endoscopic nasal surgery for pituitary tumors. The absorbable mesh is applied during surgery to enhance tissue compatibility and reduce the need for postoperative lumbar drainage. By analyzing the outcomes of patients undergoing this procedure, the study aims to provide insights into the potential benefits of using Neoveil in neurosurgery. The research will contribute to the development of new treatment protocols for managing CSF leakage.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with primary or recurrent pituitary tumors who require endoscopic nasal surgery.
Not a fit: Patients with pituitary tumors who do not require surgical treatment or those with other brain tumors may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly reduce postoperative complications and hospital stays for patients undergoing pituitary tumor surgery.
How similar studies have performed: Other studies have shown promise with similar absorbable materials in preventing CSF leakage, indicating a potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
A. Inclusion criteria 1\. Patients with primary or recurrent pituitary tumors require endoscopic nasal surgery. B. Exclusion criteria 1. Patients with pituitary gland tumors who do not receive surgical treatment. 2. Patients with other brain tumors. 3. Patients allergic to polyglycolic acid (PGA). 4. Patients who have had previous radiation therapy or chemotherapy.
Where this trial is running
Taipei
- National Taiwan University Hospital — Taipei, Taiwan (Recruiting)
Study contacts
- Principal investigator: Abel Huang, MD — National Taiwan University Hospital
- Study coordinator: Abel Huang, MD
- Email: how.how0622@gmail.com
- Phone: +8860223123456
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.